All News

This months over-the-counter (OTC) product guide highlights products that contain natural ingredients.

A diverse population and financial obstacles present unique challenges for pharmacists in Hawaii.

Two pharmacy technicians discuss why the technician career path is special to them.

Challenges for uptake of long-acting injectable pre-exposure prophylaxis in populations at risk for HIV include fear of needles, potential adverse effects, and concerns about diminished efficacy.

Pharmacy Times will be covering the American Society of Health-System Pharmacists 2022 Midyear Clinical Meeting from December 4 to 8.

Adults with attachment anxiety were more likely to misremember facts when they could see the person speaking.

An experimental drug could help scientists understand the development of mantle cell lymphoma and potentially increase overall survival.

Comedy has taught me several keys that have helped alleviate and manage burnout.

Flu vaccines can protect against severe outcomes and death, but how long does it last? Who should be getting one?

What's annoying pharmacists this month?

Pharmacists should evaluate medications for potential problems at patient meetings to improve safety.

Prior research has associated early adolescent use of hormonal contraceptives with the risk of depression in adulthood.

Parties and get-togethers often present challenges for patients with allergies, particularly with home-cooked food that may have unclear ingredients.

Data to be presented at the 45th Annual San Antonio Breast Cancer Symposium suggest that the novel sequencing test can detect signs of disease recurrence across breast cancer subtypes, improving outcomes.

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Students can begin learning about treating patients with trauma early.

Zanubrutinib expressed better cardiac safety measures, higher progression-free survival, and lower discontinuation rates in the ALPINE trial compared with compared ibrutinib.

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.

Pharmacists can coordinate education programs for patients to normalize quality of life and minimize infusion-related pain.

On this month's list of Rx products is an FDA-updated label for a cardiovascular disease drug, 2 FDA-approved NDAs for schizophrenia and alopecia areata, and an FDA approved treatment for pustular psoriasis.

GSK3036656 demonstrates early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.

The implementation of negative control outcomes and a complementary cohort demonstrate an estimated beneficial effect that associated with an individual’s overall health.

Study suggests that high levels of nicotinamide riboside could increase the risk of developing triple-negative breast cancer and may cause the cancer to metastasize to the brain.

The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.

Patients with lung cancer in an early-intervention lung screening program were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.

Patients with difficult-to-control hypertension have greater risk of heart attack, stroke, end-stage renal disease, and heart failure.

Instagram offers a myriad of ways to share content and connect with others.